Remdesivir administration for Japanese COVID-19 patients undergoing maintenance hemodialysis: a retrospective observation with six case reports

Table 1 Characteristics and clinical findings on admission, and treatment outcomes

Case		Before May 2021				After June 2021
Case		1	2	3	4	5	6	7	8	9	10	11
Gender	(M/F)	F	M	F	M	F	M	M	M	F	M	M
Age	(year)	70s	80s	70s	70s	70s	70s	40s	80s	50s	40s	60s
Dialysis vintage	(month)	336	63	5	7	21	252	0	307	26	24	27
Diabetes	(+) or (−)	(−)	(+)	(+)	(+)	(−)	(−)	(+)	(−)	(+)	(+)	(+)
Number of vaccinations	(time)	0	0	0	0	0	0	0	0	0	0	0
SpO2	(%)	82	95	95	95	89	92	95	84	95	88	94
Oxygen administration	(L/min)	0	0	0	0	0	0	0	0	0	0	0
Oxygen required to maintain SpO₂ of 93% or higher (	L/min)	1	0	1	0	2	1	1	3	0	2	1
Severity of COVID-19		Moderate II	Moderate I	Moderate I	Moderate I	Moderate	Moderate II	Mild	Moderate II	Moderate I	Moderate II	Moderate I
Serum CRP	(mg/dL)	10.33	4.88	2.18	6.06	2.98	11.20	0.10	15.43	0.24	0.99	1.12
Serum LDH	(IU/L)	267	334	282	253	280	221	411	490	250	209	274
Serum ferritin	(ng/mL)	242	170	154	30	1445	73	110	251	270	139	65
Chest CT findings		Pneumonia	None	None	Pneumonia	Pneumonia	Pneumonia	Congestion	Pneumonia	None	Pneumonia	Pneumonia
When to start remdesivir administration		Not administered	Not administered	Not administered	After becoming severe and transferring to a tertiary hospital	At the diagnosis of moderate COVID-19	At the diagnosis of moderate COVID-19	At the diagnosis of moderate COVID-19	After becoming severe (O₂ 5 L/min SpO₂ 87%)	At the diagnosis of moderate COVID-19	At the diagnosis of moderate COVID-19	At the diagnosis of moderate COVID-19
Duration to discharge	(day)		25	10		13	18	15		11	12	21
Outcome		Transferred to a tertiary hospital and died	Discharged	Discharged	Transferred to a tertiary hospital and died	Discharged	Discharged	Discharged	Died	Discharged	Discharged	Discharged

SpO₂ percutaneous oxygen saturation, COVID-19 novel coronaviral disease, CRP C-reactive protein, LDH lactate dehydrogenase, CT computed tomography

ISSN: 2059-1381